Pittsburgh based Sharp Edge Labs, a former NSIV member company, announced that it has entered into a drug discovery collaboration agreement with Sumitomo Dainippon Pharma Co. Ltd. Sharp Edge focuses on discovering drugs to treat genetic disorders of protein trafficking. CEO Scott Sneddon explained that the collaboration “takes advantage of the synergy between Sumitomo Dainippon Pharma’s expertise in CNS drug discovery and development, and Sharp Edge’s unique cellular biosensor technology.”
Read the full store here.
Leave a Comment